Q2 EPS Forecast for Kymera Therapeutics Boosted by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities research analysts at HC Wainwright increased their Q2 2025 earnings per share estimates for shares of Kymera Therapeutics in a report issued on Monday, May 12th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.77) per share for the quarter, up from their previous estimate of ($0.78). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.35) EPS, FY2027 earnings at ($3.71) EPS, FY2028 earnings at ($2.59) EPS and FY2029 earnings at ($0.72) EPS.

Several other equities research analysts have also weighed in on the company. Bank of America dropped their price target on Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating on the stock in a research report on Monday. Citigroup started coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price on the stock. Stephens reissued an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Guggenheim reissued a “buy” rating and set a $52.00 price target on shares of Kymera Therapeutics in a research note on Monday. Finally, UBS Group reduced their price target on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.27.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $30.02 on Thursday. The business’s 50 day simple moving average is $29.42 and its two-hundred day simple moving average is $37.18. The stock has a market capitalization of $1.95 billion, a P/E ratio of -12.83 and a beta of 2.18. Kymera Therapeutics has a one year low of $19.45 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s revenue was up 114.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.69) EPS.

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company’s stock, valued at $2,438,588.25. The trade was a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 over the last quarter. 16.01% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP raised its stake in Kymera Therapeutics by 13.0% in the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock valued at $164,134,000 after buying an additional 689,547 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after buying an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Kymera Therapeutics in the fourth quarter valued at $23,856,000. Boxer Capital Management LLC acquired a new stake in Kymera Therapeutics in the fourth quarter valued at $17,098,000. Finally, Janus Henderson Group PLC raised its stake in Kymera Therapeutics by 2,397.9% in the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock valued at $15,197,000 after buying an additional 362,276 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.